0000000000752219

AUTHOR

Berardi Rossana

0000-0002-9529-2960

showing 2 related works from this author

Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey.

2013

BackgroundBone metastasis represents an increasing clinical problem in advanced renal cell carcinoma (RCC) as disease-related survival improves. There are few data on the natural history of bone disease in RCC.Patients and methodsData on clinicopathology, survival, skeletal-related events (SREs), and bone-directed therapies for 398 deceased RCC patients (286 male, 112 female) with evidence of bone metastasis were statistically analyzed.ResultsMedian time to bone metastasis was 25 months for patients without bone metastasis at diagnosis. Median time to diagnosis of bone metastasis by MSKCC risk was 24 months for good, 5 months for intermediate, and 0 months for poor risk. Median number of SR…

OncologyMaleAnatomy and PhysiologyBone diseaseEpidemiologySettore MED/06 - Oncologia Medicamedicine.medical_treatmentMetastasisMetastasisbone metastasesRenal cell carcinomaBasic Cancer ResearchMedicineMusculoskeletal SystemMultidisciplinaryDiphosphonatesrenal cell carcinoma bone metastasis zoledronic acidQRBone metastasisKidney NeoplasmsOncologyItalyObservational StudiesDisease ProgressionMedicineFemaleCancer Epidemiologymedicine.drugResearch Articlemedicine.medical_specialtyClinical Research DesignSciencerenal cancerBone NeoplasmsInternal medicineHumansBonerenal cancer; bone metastasesRetrospective Studiesbusiness.industryRenal Cell CarcinomaCancerCancers and NeoplasmsBone fracturemedicine.diseaseSurgeryRadiation therapyGenitourinary Tract TumorsZoledronic acidbusiness
researchProduct

Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey

2013

BackgroundBone metastasis represents an increasing clinical problem in advanced gastric cancer (GC) as disease-related survival improves. In literature, few data on the natural history of bone disease in GC are available.Patients and methodsData on clinicopathology, skeletal outcomes, skeletal-related events (SREs), and bone-directed therapies for 208 deceased GC patients with evidence of bone metastasis were statistically analyzed.ResultsMedian time to bone metastasis was 8 months (CI 95%, 6.125-9.875 months) considering all included patients. Median number of SREs/patient was one. Less than half of the patients (31%) experienced at least one and only 4 and 2% experienced at least two and …

OncologyAdultMalemedicine.medical_specialtyPathologyBone diseaseSettore MED/06 - Oncologia Medicamedicine.medical_treatmentScienceBone NeoplasmsMetastasisgastric cancer; bone metastasisStomach NeoplasmsInternal medicinemedicineHumansskeletal disease advanced hepatocellular carcinomaskeletal-related events bisphosphonateAdult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Patient Outcome Assessment; Population Surveillance; Prognosis; Retrospective Studies; Stomach NeoplasmsNeoplasm Metastasisbone metastasisAgedRetrospective StudiesMultidisciplinaryBone Density Conservation AgentsDiphosphonatesbusiness.industrygastric cancerQRBone metastasisCancerBone fractureMiddle Agedmedicine.diseasePrognosisRadiation therapyPatient Outcome AssessmentBone Density Conservation AgentsZoledronic acidPopulation SurveillanceMedicineFemalebusinessmedicine.drugResearch Article
researchProduct